H.R. 8143 · 119th Congress · Health
Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.
- IntroducedMar 27, 2026 Done
- CommitteeReferred to 2 committees Current stage
- House floorNot yet Not reached yet
- Senate floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
Full text
No CRS summary yet · 488 wordsH.R. 8143 · Introduced in House · Mar 27, 2026
This Act may be cited as the Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.
Section 1860D–4(b)(3) of the Social Security Act ( 42 U.S.C. 1395w–104(b)(3) ) is amended by adding at the end the following new subparagraph: (J) Required inclusion of certain generic drugs and biosimilar biological products (i) In general With respect to a plan year beginning on or after January 1, 2027, the formulary shall include in a preferred position relative to the reference drug— (I) each covered generic drug for which the wholesale acquisition cost is less than the wholesale acquisition cost of the reference drug of such covered generic drug; and (II) at least two covered bio-similar biological products for which the wholesale acquisition cost is less than the wholesale acquisition cost of the reference biological product of such covered biosimilar biological product. (ii) Prohibition on certain lim-its on access The PDP sponsor offering the prescription drug plan may not impose limits on access to a covered generic drug required to be included on the formulary under clause (i)(I) or a covered biosimilar biological product required to be included on the formulary under clause (i)(II), including through utilization management techniques such as prior authorization, or step therapy, that are more restrictive than any such limits imposed on access to the reference drug of such covered generic drug or reference biological product of such covered biosimilar biological product, respectively, or that otherwise have the effect of limiting the availability to enrollees of such covered generic drug or covered biosimilar biological product relative to such reference drug or reference biological product over such covered generic drug or covered biosimilar biological product, respectively. (iii) Definitions In this subparagraph and subparagraph (J): (I) Covered biosimilar biological product The term covered biosimilar biological product means a covered part D drug that is a biosimilar biological product (as defined in section 1847A(c)(6)(H)). (II) Covered generic drug The term covered generic drug means a covered part D drug that is a drug described in section 1860D–2(e)(1)(A) and approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act. (III) Preferred position The term preferred position means a product is placed on a more favorable formulary tier and has lower patient out-of-pocket costs than the corresponding reference drug or reference biological product. (IV) Reference biological product The term reference biological product has the meaning given such term in section 1847A(c)(6)(I). (V) Reference drug The term reference drug means, with respect to a covered generic drug, the listed drug (as described in clause (i) of section 505(j)(2)(A) of the Federal Food, Drug, and Cosmetic Act) that is referred to in the abbreviated application for such covered generic drug under such section. (VI) Wholesale acquisition cost The term wholesale acquisition cost has the meaning given such term in section 1847A(c)(6)(B). .
Shown here because the text is under 500 words. Open on Congress.gov
Who lobbies on it
3 organizations, more than 86% of House bills · 8 filings · Q1 2026–Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Pharmaceutical Care Management Association
3 of 3 quarters
“…PBM Price Transparency and Accountability Act S.4323/ H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 S. 5586; Ensuring Accurate Payments to Specialty Pharmacies Act H.R. 4317; PBM Reform Act H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 7148; Consolidated…”
$9.5M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Prime Therapeutics
3 of 3 quarters
“H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related…”
$360K lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Amgen Inc
2 of 3 quarters
“…HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act”
$8.2M lobbying spend in 2026 to date, all issuesQ3 2026 filing
Organizations that named H.R. 8143 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- Mar 27, 2026Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Mar 27, 2026Introduced in House